Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 10/2009

01-10-2009 | Original Article

Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells

Authors: Craig Gedye, Juliet Quirk, Judy Browning, Suzanne Svobodová, Thomas John, Pavel Sluka, P. Rod Dunbar, Denis Corbeil, Jonathan Cebon, Ian D. Davis

Published in: Cancer Immunology, Immunotherapy | Issue 10/2009

Login to get access

Abstract

“Cancer stem cells” that resist conventional treatments may be a cause of therapeutic failure in melanoma. We report a subpopulation of clonogenic melanoma cells that are characterized by high prominin-1/CD133 expression in melanoma and melanoma cell lines. These cells have enhanced clonogenicity and self-renewal in vitro, and serve as a limited in vitro model for melanoma stem cells. In some cases clonogenic CD133+ melanoma cells show increased expression of some cancer/testis (CT) antigens. The expression of NY-ESO-1 in an HLA-A2 expressing cell line allowed CD133+ clonogenic melanoma cells to be targeted for killing in vitro by NY-ESO-1-specific CD8+ T-lymphocytes. Our in vitro findings raise the hypothesis that if melanoma stem cells express CT antigens in vivo that immune targeting of these antigens may be a viable clinical strategy for the adjuvant treatment of melanoma.
Appendix
Available only for authorised users
Literature
1.
Thompson JF, Scolyer RA, Kefford RF (2005) Cutaneous melanoma. Lancet 365:687–701PubMed
2.
Phan GQ, Yang JC, Sherry RM et al (2003) Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100:8372–8377PubMedCrossRef
3.
Morgan RA, Dudley ME, Wunderlich JR et al (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314:126–129PubMedCrossRef
4.
Cebon J, Gedye C, John T et al (2007) Immunotherapy of advanced or metastatic melanoma. Clin Adv Hematol Oncol 5:994–1006PubMed
5.
Reya T, Morrison SJ, Clarke MF et al (2001) Stem cells, cancer, and cancer stem cells. Nature 414:105–111PubMedCrossRef
6.
Dalerba P, Cho RW, Clarke MF (2007) Cancer stem cells: models and concepts. Annu Rev Med 58:267–284PubMedCrossRef
7.
8.
Brabletz T, Jung A, Spaderna S et al (2005) Opinion: migrating cancer stem cells—an integrated concept of malignant tumour progression. Nat Rev Cancer 5:744–749PubMedCrossRef
9.
Kim JJ, Tannock IF (2005) Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer 5:516–525PubMedCrossRef
10.
Frank NY, Margaryan A, Huang Y et al (2005) ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res 65:4320–4333PubMedCrossRef
11.
Fang D, Nguyen TK, Leishear K et al (2005) A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 65:9328–9337PubMedCrossRef
12.
Klein WM, Wu BP, Zhao S et al (2007) Increased expression of stem cell markers in malignant melanoma. Mod Pathol 20:102–107PubMedCrossRef
13.
Monzani E, Facchetti F, Galmozzi E et al (2007) Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer 43:935–946PubMedCrossRef
14.
Schatton T, Murphy GF, Frank NY et al (2008) Identification of cells initiating human melanomas. Nature 451:345–349PubMedCrossRef
15.
Quintana E, Shackleton M, Sabel MS et al (2008) Efficient tumour formation by single human melanoma cells. Nature 456:593–598PubMedCrossRef
16.
17.
Nicholaou T, Ebert L, Davis ID et al (2006) Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1. Immunol Cell Biol 84:303–317PubMedCrossRef
18.
Simpson AJ, Caballero OL, Jungbluth A et al (2005) Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 5:615–625PubMedCrossRef
19.
Jäger D, Taverna C, Zippelius A et al (2004) Identification of tumor antigens as potential target antigens for immunotherapy by serological expression cloning. Cancer Immunol Immunother 53:144–147PubMedCrossRef
20.
Yang B, O’Herrin SM, Wu J et al (2007) MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. Cancer Res 67:9954–9962PubMedCrossRef
21.
Laduron S, Deplus R, Zhou S et al (2004) MAGE-A1 interacts with adaptor SKIP and the deacetylase HDAC1 to repress transcription. Nucleic Acids Res 32:4340–4350PubMedCrossRef
22.
23.
Davis ID, Chen W, Jackson H et al (2004) Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci USA 101:10697–10702PubMedCrossRef
24.
Fargeas CA, Fonseca A-V, Huttner WB et al (2006) Prominin–1 (CD133): from progenitor cells to human diseases. Future Lipidol 1:213–225CrossRef
25.
Singh SK, Hawkins C, Clarke ID et al (2004) Identification of human brain tumour initiating cells. Nature 432:396–401PubMedCrossRef
26.
Belicchi M, Pisati F, Lopa R et al (2004) Human skin-derived stem cells migrate throughout forebrain and differentiate into astrocytes after injection into adult mouse brain. J Neurosci Res 77:475–486PubMedCrossRef
27.
Gibbs P, Hutchins AM, Dorian KT et al (2000) MAGE-12 and MAGE-6 are frequently expressed in malignant melanoma. Melanoma Res 10:259–264PubMedCrossRef
28.
Carey TE, Takahashi T, Resnick LA et al (1976) Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells. Proc Natl Acad Sci USA 73:3278–3282PubMedCrossRef
29.
Karbanova J, Missol-Kolka E, Fonseca AV et al (2008) The stem cell marker CD133 (Prominin-1) is expressed in various human glandular epithelia. J Histochem Cytochem 56:977–993PubMedCrossRef
30.
Barrow C, Browning J, MacGregor D et al (2006) Tumor antigen expression in melanoma varies according to antigen and stage. Clin Cancer Res 12:764–771PubMedCrossRef
31.
Jungbluth AA, Chen YT, Busam KJ et al (2002) CT7 (MAGE-C1) antigen expression in normal and neoplastic tissues. Int J Cancer 99:839–845PubMedCrossRef
32.
Vaughan HA, Svobodova S, MacGregor D et al (2004) Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1. Clin Cancer Res 10:8396–8404PubMedCrossRef
33.
Chen JL, Dunbar PR, Gileadi U et al (2000) Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL. J Immunol 165:948–955PubMed
34.
Lev DC, Onn A, Melinkova VO et al (2004) Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo. J Clin Oncol 22:2092–2100PubMedCrossRef
35.
Grichnik JM, Burch JA, Schulteis RD et al (2006) Melanoma, a tumor based on a mutant stem cell? J Invest Dermatol 126:142–153PubMedCrossRef
36.
Clarke MF (2005) A self-renewal assay for cancer stem cells. Cancer Chemother Pharmacol 56(Suppl 7):64–68PubMedCrossRef
37.
Jaksch M, Munera J, Bajpai R et al (2008) Cell cycle-dependent variation of a CD133 epitope in human embryonic stem cell, colon cancer, and melanoma cell lines. Cancer Res 68:7882–7886PubMedCrossRef
38.
Herlyn M, Balaban G, Bennicelli J et al (1985) Primary melanoma cells of the vertical growth phase: similarities to metastatic cells. J Natl Cancer Inst 74:283–289PubMed
39.
Lee J, Kotliarova S, Kotliarov Y et al (2006) Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9:391–403PubMedCrossRef
40.
Li A, Walling J, Kotliarov Y et al (2008) Genomic changes and gene expression profiles reveal that established glioma cell lines are poorly representative of primary human gliomas. Mol Cancer Res 6:21–30PubMedCrossRef
41.
De Witt Hamer PC, Van Tilborg AA, Eijk PP et al (2008) The genomic profile of human malignant glioma is altered early in primary cell culture and preserved in spheroids. Oncogene 27:2091–2096PubMedCrossRef
42.
Vogl A, Sartorius U, Vogt T et al (2005) Gene expression profile changes between melanoma metastases and their daughter cell lines: implication for vaccination protocols. J Investig Dermatol 124:401–404PubMedCrossRef
43.
Sigalotti L, Covre A, Zabierowski S et al (2008) Cancer testis antigens in human melanoma stem cells: expression, distribution, and methylation status. J Cell Physiol 215:287–291PubMedCrossRef
44.
Gjerstorff MF, Johansen LE, Nielsen O et al (2006) Restriction of GAGE protein expression to subpopulations of cancer cells is independent of genotype and may limit the use of GAGE proteins as targets for cancer immunotherapy. Br J Cancer 94:1864–1873PubMedCrossRef
45.
Adair SJ, Hogan KT (2008) Treatment of ovarian cancer cell lines with 5-aza–2′-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules. Cancer Immunol Immunother. doi:10.​1007/​s00262-008-0582-6
46.
Rappa G, Fodstad O, Lorico A (2008) The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma. Stem Cells 26:3008–3017PubMedCrossRef
47.
48.
Smith LM, Nesterova A, Ryan MC et al (2008) CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer 99:100–109PubMedCrossRef
49.
Florek M, Haase M, Marzesco AM et al (2005) Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer. Cell Tissue Res 319:15–26PubMedCrossRef
50.
Ponta H, Sherman L, Herrlich PA (2003) CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 4:33–45PubMedCrossRef
51.
52.
Ménard C, Martin F, Apetoh L et al (2008) Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. Cancer Immunol Immunother 57:1579–1587PubMedCrossRef
53.
Mine T, Matsueda S, Li Y et al (2008) Breast cancer cells expressing stem cell markers CD44(+) CD24 (lo) are eliminated by Numb-1 peptide-activated T cells. Cancer Immunol Immunother. doi:10.​1007/​s00262-008-0623-1
Metadata
Title
Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells
Authors
Craig Gedye
Juliet Quirk
Judy Browning
Suzanne Svobodová
Thomas John
Pavel Sluka
P. Rod Dunbar
Denis Corbeil
Jonathan Cebon
Ian D. Davis
Publication date
01-10-2009
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 10/2009
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-009-0672-0

Other articles of this Issue 10/2009

Cancer Immunology, Immunotherapy 10/2009 Go to the issue

Original Article

Patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells elicit anti-tumor activity: in vitro results and clinical responses

Original Article

Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax (MVA-5T4)

Original Article

Activation of tumor-specific T lymphocytes after laser-induced thermotherapy in patients with colorectal liver metastases

Original Article

Unconventional cytokine profiles and development of T cell memory in long-term survivors after cancer vaccination

Review

A systematic review of humoral immune responses against tumor antigens

Original Article

Incubation of antigen-sensitized T lymphocytes activated with bryostatin 1 + ionomycin in IL-7 + IL-15 increases yield of cells capable of inducing regression of melanoma metastases compared to culture in IL-2
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits